CLINICAL SIGNIFICANCE OF SLC22A1 RS622342 GENETIC POLYMORPHISMIN TYPE 2 DIABETES MELLITUS PATIENTS, TAKING METFORMIN


Cite item

Full Text

Abstract

One of the key proteins that determine the pharmacokinetics of metformin is OCT1. rs622342 polymorphism in the gene SLC22A1 (OCT1) can reduce the expression of this protein. The aim of this study was to evaluate clinical significance of rs622342 in people with diabetes mellitus (DM) type 2, taking metformin. In 94 patients dynamics of the main indicators of glycemic control and body mass index were sudied over 6 months of treatment. At the end of the study 33 of 49 patients (67,3%) with wild-type variant of rs622342 (genotype AA) and 17 of 45 (37,7%) with polymorphic variants of the gene SLC22A1 (AC- and CC-genotypes) were taken metformin only and had Hb A1c levels less than 7,0%. Remaining patients required a second hypoglycemic agent or had Hb A1c levels 7,0% or more. Calculating odds ratios showed that the presence of AC- or CC- genotypes of rs622342 in the gene SLC22A1 increases the risk of poor clinical effect of metformin 3,4-fold (p = 0,004). Conclusion: The presence of a polymorphic allele C ( rs622342 ) in the gene SLC22A1 in patients with type 2 diabetes is associated with poor clinical effect of metformin monotherapy.

About the authors

V L Baranov

North-Western State Medical University named after I.I.Metchnikov

N V Vorokhobina

North-Western State Medical University named after I.I.Metchnikov

M Abulula

North-Western State Medical University named after I.I.Metchnikov

K A Zagorodnikova

North-Western State Medical University named after I.I.Metchnikov

A A Topanova

North-Western State Medical University named after I.I.Metchnikov

References

  1. Inzucchi S. E., Bergenstal R. M., Buse J. B., Diamant M., Ferrannini E., Nauck M. et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) // Diabetes Care. - 2012. - Vol. 35. - P. 1364-1379.
  2. Rena G., Pearson E. R., Sakamoto K. Molecular mechanism of action of metformin: old or new insights? // Diabetologia. - 2013. - Vol. 56. - №9. - P. 1898-1906.
  3. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS// Lancet. - 1998. - Vol. 352. - P. 854-865.
  4. Noto H., Goto A., Tsujimoto T., Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis // PLoS One. - 2012. - Vol. 7. - №3. - e33411.
  5. Graham G. G., Punt J., Arora M., Day R. O., Doogue M. P., Duong J. K., Furlong T. J., Greenfield J. R., Greenup L. C., Kirkpatrick C. M., Ray J. E., Timmins P., Williams K. M. Clinical pharmacokinetics of metformin. // Clin. Pharmacokinet. - 2011. - Vol. 50. - №2. - P. 81-98.
  6. Christensen M. M., Brasch-Andersen C., Green H., Nielsen F., Damkier P., Beck-Nielsen H., Brosen K. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet. // Genomics. - 2011. - Vol. 21. - № 12. - P. 837-850.
  7. Muller J., Lips K. S., Metzner L., Neubert R. H., Koepsell H., Brandsch M. Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). // Biochem. Pharmacol. - 2005. - Vol. 70. - №12. - P. 1851-1860.
  8. Shu Y., Sheardown S. A., Brown C. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. // J. Clin. Invest. - 2007. - Vol. 117. - № 5. - P. 1422-1431.
  9. Gong L., Goswami S., Giacomini K. M., Altman R. B., Klein T. E. Metformin pathways: pharmacokinetics and pharmacodynamics. // Pharmacogenet. Genomics. - 2012. - Vol. 22. - № 11. - P. 820-827.
  10. Becker M. L., Visser L. E., van Schaik R. H., Hofman A., Uitterlinden A. G., Stricker B. H. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. // Pharmacogenomics J. - 2009. - Vol. 9. - № 4. - P. 242-247.
  11. Tkáč I., Klimcakova L., Javorsky M., Fabianová M, Schroner Z, Hermanová H, Babjaková E, Tkáčová R. Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in Type 2 diabetes. // Diabetes Obes. Metab. - 2013. - Vol. 15. - № 2. - P. 189-191.
  12. Umamaheswaran G., Praveen R. G., Damodaran S. E., Das A. K., Adithan C. Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patients // Clin. Exp. Med. - 2014. URL: http://www.ncbi.nlm.nih.gov/pubmed/25492374 (дата обращения: 05.01.2015).
  13. Клинические рекомендации «Алгоритмы специализированной медицинской помощи больным сахарным диабетом» / под ред. И. И. Дедова, М. В. Шестаковой. 6-й выпуск // Сахарный диабет. - 2013. - №1S.- 120 с.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Baranov V.L., Vorokhobina N.V., Abulula M., Zagorodnikova K.A., Topanova A.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).